IMPORTANCE Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with manifold consequences for mammalian pathophysiology, including cardiovascular disease. A deeper understanding of TNF-α biology may enhance treatment precision.
T umor necrosis factor α (TNF-α) is a proinflammatory cytokine with pleiotropic effects in human health and disease. In addition to its well-characterized pathogenic contributions to inflammatory and autoimmune diseases, atherosclerosis, type 2 diabetes, and cancer, TNF-α also plays a key homeostatic role in pathogen defense, tissue repair and regeneration, and organ development. 1 Therapeutic inhibition of TNF-α has been used in clinical settings, both successfully (eg, in various forms of autoimmune diseases) and unsuccessfully (eg, in multiple sclerosis). 2 Furthermore, treatment with TNF inhibitors has long been known to lower the risk of cardiovascular disease among patients with autoimmune disease, 3 and currently several trials 4 are assessing cardioprotective effects of inhibiting inflammatory cytokines. Recently, the randomized placebo-controlled CANTOS trial 5, 6 reported significant reductions in recurrent cardiovascular risk associated with interleukin 1β inhibition, which was achieved independently of changes in lipid levels. While such findings highlight the clinical promise of targeting systemic inflammation in the context of cardiovascular disease, the underlying mechanisms of action remain elusive. Circulating concentrations of TNF-α have a moderate genetic determinant, with heritability estimates ranging from 17% 7 to 39% 8 in large-scale European twin studies to 68% in a Ugandan community with a high prevalence of tuberculosis. Known common mutations account for a small fraction of that heritable component, explaining less than 4% of TNF-α variance in a recent meta-analysis of genome-wide association studies (written communication, B. Z. Alizadeh, MD, MSc, PhD, June 30, 2017) . Emerging evidence suggests that epigenetic processes, such as DNA methylation, that reflect changes in gene expression that occur without sequence mutations, may offer promising clues in the search for missing TNF-α heritability. For example, methylation of cytosine-phosphateguanine (CpG) loci in the TNF promoter was associated with TNF-α expression and plasma TNF-α levels in several population-based studies. 10, 11 In vitro, experimental manipulation of DNA methylation has been shown to alter the ability of cells to produce TNF-α, 12 offering causal support for the association observed in population studies. To our knowledge, however, no study to date has comprehensively examined DNA methylation across the entire genome in association with circulating levels of TNF-α in large human populations, or has assessed TNF-α epigenetics with regards to cardiovascular risk.
Therefore we conducted what is, to our knowledge, the first epigenome-wide meta-analysis of associations between circulating TNF-α levels and DNA methylation in whole-blood samples or isolated lymphocytes in 4794 individuals in the Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) consortium. We subsequently achieved replication of the top CpG loci in an independent population of 816 individuals, evaluated the associations between DNA methylation and cis gene expression, and assessed genotype contributions to the observed CpG methylation variation in the regions of interest.
Finally, we investigated the association of the top epigenetic correlates of circulating TNF-α concentrations with incident coronary heart disease (CHD) in a meta-analysis that included 11 461 participants who experienced 1895 CHD events (coronary insufficiency, coronary revascularization, recognized myocardial infarction, and coronary death). For this purpose, we added the data of 4 additional study cohorts.
Methods

Discovery and Replication Populations
In the discovery phase, the epigenome-wide study included individuals of European descent from 6 studies participating in the CHARGE consortium 13 : the Framingham Heart Study (FHS), the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) study, the Invecchiare in Chianti Study (InCHI-ANTI), the Kooperative Gesundheitsforschung in der Region Augsburg cohort (KORA), the Lothian Birth Cohort 1921 (LBC1921), and the Normative Aging Study (NAS). Two additional Finnish cohorts, the Northern Finland Birth Cohort 1966 (NFBC66) and the Helsinki Birth Cohort Study (HBCS), were designated for replication. (The NAS and HBCS cohorts were excluded from the main analysis because of the extreme variability in TNF-α measurements [ Table 1 ], which could be because of the poor performance of multiplexed assays compared with enzyme-linked immunosorbent assays [ELISA] , as previously reported. 14 ) Finally, a Dutch cohort, the Rotterdam Study (RS), was excluded from the main epigenetic analyses because it does not have TNF-α measurements, but was included in the subsequent analyses because the data set did include DNA methylation, DNA sequence, and gene expression data. Individuals in any of the studies who had reported an autoimmune diagnosis or were taking immune-modulating agents (eg, TNF-α blockers) were not included in the analyses. Further details about each study are included in Table 1 and in eMethods 1 in the Supplement.
This study was approved by the institutional review board of the University of Alabama at Birmingham. All protocols of analyzed studies were approved by the institutional review boards of the participating study sites. All participants provided written informed consent.
Key Points
Question Is DNA methylation in peripheral blood cells associated with circulating tumor necrosis factor α levels and risk of coronary heart disease?
Findings In this epigenome-wide study, top methylation loci associated with circulating tumor necrosis factor α concentration in whole blood or CD4+ T cells were located in or near the DTX3L-PARP9 gene complex, NLRC5, and ABO. The findings in NLRC5 and DTX3L-PARP9 were successfully replicated and linked to gene expression, and methylation at these loci was robustly inversely associated with the risk of incident coronary heart disease.
Meaning After further validation, these epigenetic associations might be useful in the pursuit of new or improved therapeutic applications.
Laboratory Measurements
Circulating TNF-α concentrations were measured in picograms per milliliter using the approaches listed in Table 1 . In all but 2 cohort (FHS and RS), TNF-α concentrations were measured at the same time and center visit as blood samples were drawn for the quantification of DNA methylation. In the FHS cohort, TNF-α was measured in the same individuals approximately 7 years prior to the DNA methylation assay. In the RS cohort, no TNF-α measurements were ever made.
Circulating TNF-α concentration was natural log-transformed (lnTNF-α) to reduce the skewness of the distribution. Individuals whose lnTNF-α measurements were more than 4 SDs away from the cohort mean (n = 19) were excluded from subsequent analyses.
DNA Methylation Measurements, Normalization, and Quality Control
All studies used the Illumina Infinium Human Methylation 450 Beadchip (Illumina Inc) to quantify epigenome-wide DNA methylation. In all studies that conducted TNF-α measurements but 1, these measurements were performed on DNA extracted from whole-blood samples; the GOLDN study isolated and quantified DNA methylation on CD4+ T cells. Study-specific approaches to methylation data processing are summarized in eTable 1 in the Supplement.
Statistical Analyses
In the discovery phase, each cohort fit 3 linear mixed-effect regression models to assess associations between lnTNF-α (predictor) and normalized methylation β scores (outcomes). The base model adjusted for age and sex as fixed effects and for technical covariates (array, row, and/or column number) as a random effect. The second model additionally adjusted for white blood cells subtypes for studies reporting methylation in whole-blood samples. The third model adjusted for the same covariates as the second model, plus smoking (current, former, or never) and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared). All covariates were selected based on their known associations with DNA methylation. Cohorts additionally adjusted for relatedness or other study-specific covariates as necessary (eTable 2 in the Supplement). Results from the 5 cohorts participating in the main discovery analysis were meta-analyzed using a fixedeffects, inverse-variance-weighted approach in METASOFT, version 2.0 (University of California-Los Angeles).
15 Because the GOLDN study was the only cohort that used CD4+ T cells and not whole-blood samples, we ran a sensitivity metaanalysis excluding GOLDN data. We performed additional sensitivity analyses including the NAS and the HBCS, which were cohorts with extremely variable Milliplex-measured TNF-α results.
To maximize statistical power of discovery, we carried CpG sites forward to the replication phase if the false discovery rate for the specific CpG site was less than 0.05. The models used in the replication analysis were identical to those implemented in the discovery phase. To minimize the chance of false positives, we implemented a more stringent Bonferroni correction in the replication phase: 0.05 per number of statistically significant hits from the discovery meta-analysis.
Gene Expression Measurements and Analysis
The CpG sites that significantly replicated in the independent replication sample were further tested for association with cis gene expression in whole-blood samples from 3738 participants with available gene expression measurements (from the FHS, KORA, and RS cohorts). Methods for the expression measurements and analysis are described in eMethods 2 in the Supplement. Messenger RNA (mRNA) transcripts that achieved statistical significance in at least 2 cohorts were further evaluated for association with circulating TNF-α concentration in the FHS cohort, using regression models adjusted for age, sex, imputed white blood cell counts, smoking, BMI, and technical covariates.
Integrating DNA Methylation and Sequence Data
To establish genetic contributions to the observed methylation of the top loci, we studied genetic associations with DNA methylation in cis genes (within 20 kb) using the GOLDN study as the discovery cohort and RS as the replication population. Genotyping, imputation procedures, and statistical analysis for both cohorts are described in eMethods 3 in the Supplement. The variants that achieved nominal significance in the replication phase were tested for association with circulating TNF-α concentration in the GOLDN cohort using linear mixed models adjusting for age, sex, study site (fixed effects), and relationships between participating family members (random effect).
In addition to methylation quantitative trait loci analyses, we searched for overlap with the genomic regions containing the replicated sites in 2 genome-wide association study (GWAS) catalogs 16, 17 to assess previously reported associations of sequence variants in the regions of interest with disease traits.
Associations With Incident CHD 
Results
General Characteristics
Demographic and TNF-α characteristics of all participating cohorts are summarized in 
Meta-analysis, Replication, and Sensitivity Analyses
The 3 models fit to test associations between epigenomewide methylation and TNF-α levels yielded similar results ( Table 2 ; eTables 3 and 4 in the Supplement); namely, the cg16411857 site in the NLR family CARD domain containing 5 genes (NLRC5) emerged as the top hit with all approaches. Based on prior evidence that supports adjusting epigenetic models for smoking and BMI, 19 all subsequent analyses focused on the third model. The results of the epigenome-wide analyses are summarized in Table 2 and visualized in Figure and eFigure 1 in the Supplement. Seven CpG sites located in 3 genomic regions emerged as the top hits in the discovery stage (each of which had a false-discovery rate <0.05). Of those, 3 CpG sites, 2 located in NLRC5 and 1 in the deltex E3 ubiquitin ligase 3L/poly (ADP-ribose) polymerase family member 9 gene complex (DTX3L/PARP9), were replicated in the 677 individuals from the NFBC66 cohort. All replicated associations were in the same direction and had comparable effect sizes. Another locus in DTX3L/PARP9 (cg00959259) was unable to undergo replication because of insufficient quality control procedures in the NFBC66 cohort; however, because of its proximity and similarity of associations to the replicated site cg08122652, we included it in subsequent analyses.
Inclusion of the 2 cohorts that measured TNF-α levels using the Milliplex method, namely the NAS cohort in the discovery phase (eTable 5 in the Supplement) and the HBCS cohort in the replication sample, increased genomic inflation by 19% (λ = 0.94 in the main analysis vs λ = 1.13 with the NAS cohort included). While the NLRC5 and DTX3L/PARP9 hits still emerged as significant in the discovery stage, none were replicated in the HBCS cohort. Excluding the GOLDN cohort from the discovery stage because of differences in methylation measurements (CD4+ T cells vs whole-blood samples) yielded 5 of the 7 significant hits observed in the main analysis, including the NLRC5 and DTX3L/PARP9 loci (eTable 6 in the Supplement).
Methylation vs Expression vs Circulating TNF-α
In an expression Quantitative Trait Methylation (eQTMs) assessment of the association between DNA expression and methylation, we observed 9 cis-eQTMs (methylationexpression pairs), pairs of 4 TNF-α-associated methylation loci and expression of cis genes in the FHS cohort. All were robust in the RS cohort, but none reached significance in the KORA cohort. The CpG-transcript pairs that satisfied the Bonferroni threshold in at least 2 cohorts are presented in Table 3 . The direction of association was negative for all transcripts except the methylation with karyopherin subunit alpha 1 gene (KPNA1) pair, and the magnitude of associations were consistent between the FHS and RS cohorts. Of the 5 transcripts that were significantly associated with TNF-α-linked CpG sites in both the FHS cohort and the RS cohort (NLRC5, DTX3L, KPNA1, PARP9, and the poly [ADP-ribose] 
Methylation vs Sequence Variation vs Circulating TNF-α Levels
Of all significant methylation correlates of TNF-α concentration, only cg07839457 showed nominally significant replication of associations with 2 neighboring NLRC5 sequence variants: rs17369768 and a deletion at the 57042641 position on chromosome 16. Of all significant methylation correlates of TNF-α concentration, only cg07839457 showed nominally significant replication of associations with 2 neighboring NLRC5 sequence variants: rs17369768 ( 05; eTable7 in the Supplement). Neither locus was significantly associated with circulating TNF-α in the GOLDN study. However, rs17369768 was nominally associated with visceral adipose tissue volume, waist circumference, weight, psoriasis, and rheumatoid arthritis in public databases.
17
Associations With Incident CHD
Methylation at all 4 TNF-α-associated loci was robustly negatively associated with the risk of incident CHD in the metaanalysis of CHARGE consortium cohorts (Table 4 ; eFigure 2 in the Supplement). Adjusted for the appropriate covariates, each 
DTX3L-PARP9 ABO NLRC5
This graph includes the data of 4163 participants in the discovery analyses. The red horizontal line denotes the threshold false detection rate of .05 for statistical significance. ).
GWAS Catalog Lookup and Functional Annotation
Of the 3 common single-nucleotide polymorphisms (SNPs) in or near NLRC5 that were reported in the GWAS catalog, 2 (rs821470 and rs17290922) were associated with schizophreniarelated phenotypes. 20, 21 The closest reported variant to the DTX3L/PARP9 locus (rs2173763) was associated with major depressive disorder. 22 Conversely, a search for SNPs previously reported to be associated with circulating TNF-α levels in the regions harboring the replicated epigenetic hits yielded no results. However, an ABO polymorphism from a region that emerged as a top hit, yet did not replicate, was identified as a TNF-α protein quantitative trait locus in an earlier analysis of KORA data.
23
Bioinformatic regulatory annotations for the DTX3L/ PARP9 and NLRC5 regions are presented in eFigures 3 and 4, respectively, in the Supplement. Both sets of loci overlap or are adjacent to regulatory elements, supporting observed associations with gene expression.
Discussion
Using epigenome-wide data from adult participants of European descent, we have identified and replicated novel associations between leukocyte DNA methylation loci in 2 genomic regions mapping to NLRC5 and DTX3L/PARP9, the expression of corresponding genes, and circulating TNF-α levels. Most notably, DNA methylation at the same loci that were correlated with lower plasma TNF-α levels was also associated with a substantial reduction in the risk of incident CHD in this multiethnic, well-powered meta-analysis.
Both genomic regions that were discovered and validated in our analysis encode proteins that play a pivotal role in the immune response. The NLRC5 genomic region is a specific transactivator of major histocompatibility complex class I genes, 24 which encode human leukocyte antigen proteins that set off the adaptive immune reaction. 25 These processes are induced chiefly by interferon γ (IFN-γ) stimulation, although also by toll-like receptor ligands, other interferons, and viral infections. 26 By activating CD8+ T cells via major histocompatibility complex class I proteins, NLRC5 has also been shown to upregulate IFN-γ, creating a positive feedback loop that ensures an effective response to intracellular pathogens.
27
The role of NLRC5 as a master regulator of the immune response, combined with its remarkable specificity, has positioned it as a promising therapeutic target in multiple clinical settings. The specific methylation loci that emerged as our top findings, cg16411857 and cg07839457, have been shown to be significantly more likely to be hypomethylated in blood samples from immune-suppressed individuals living with HIV and to also correlate negatively with viral load. 28 In another whole-blood DNA methylation study, both CpG sites were linked to circulating interleukin 18, which offered a possible mechanism for the association we observed with CHD incidence. 28 A clinically interesting detail was that the NLRC5 promoter (and specifically the cg16411857 locus) was shown to be hypermethylated in 13 distinct cancer types, with a corresponding reduction in expression of not only NLRC5, but also other genes in the major histocompatibility complex class I family, which provides a mechanism for evasion of CD8+ T lymphocyte antitumor activity. 29 Therefore, this study adds to the robust body of evidence in support of NLRC5 involvement in a wide range of pathophysiologic conditions. Similarly to NLRC5, increased expression of DTX3L-PARP9 has been shown to enhance IFN-γ signaling and therefore host immune response. 30 Recent evidence suggests that DTX3L-PARP9 may also play a key role in vascular inflammation and atherosclerosis. In macrophage-like cell lines stimulated with IFN-γ, experimental silencing of PARP9 has suppressed the induction of TNF-α (which was consistent with the directions of association observed in our analyses); silencing of PARP14 has had opposite effects (in contrast with our observations). Additionally, PARP14 deficiency was shown to promote atherogenesis in mice. 31 Possible explanations for the discrepancy in the direction of association may include the tested cell type (macrophages vs T lymphocytes or whole blood); tightly controlled experimental conditions in cell culture or murine models vs observational data from free-living humans; chance; or other factors. Therapeutic inhibition of other PARP enzymes (specifically PARP1) has also been shown to confer cardioprotective effects, 32 as well as to reduce circulating TNF-α levels in vivo. 33 Although the inconsistency of the PARP14 finding across studies merits close attention in future investigations, our analysis contributes to growing evidence linking PARP enzymes with systemic inflammation and CHD.
31
In follow-up analyses, we found only limited evidence of genotype contributions to the methylation of the CpG sites of interest, suggesting the importance of environmental determinants. A prior analysis of the GOLDN study reported moderate heritabilities for the top loci associated with TNF-α levels in our analysis, with some of them (eg, cg07839457) likely to be enriched in the genomic regions that evade erasure during embryogenesis.
34 It is therefore possible that the methylation of loci such as cg07839457 in NLRC5 could be programmed by environmental exposures (notably pathogens) and transmitted across generations, although further targeted studies are needed to rigorously test this hypothesis.
To our knowledge, the presented analysis is the largest epigenetic study of circulating TNF-α levels to date, both in sample size and scope. Previously, a number of studies have assessed relationships between methylation in the tumor necrosis factor gene (TNF) gene promoter, corresponding gene expression (where available), and circulating TNF-α levels in various disease contexts (eg, rheumatoid arthritis, 35 chronic periodontitis, 35,36 type 1 diabetes, 37 or obesity 10 ). Interestingly, TNF was not among the top regions associated with circulating TNF-α levels in our meta-analysis or in published GWAS of TNF-α levels. 23 Furthermore, there was little overlap between findings of our epigenome-wide meta-analysis and previous GWAS of TNF-α levels. The only exception concerns our observed but unreplicated association between TNF-α levels and methylation loci in ABO, α 1-3-N-acetylgalactosaminyltransferase, and α 1-3-galactosyltransferase gene (ABO), which were also observed in a previous protein quantitative trait loci GWAS, 23 which presented evidence that the effect was assay-specific and may be driven by cross-reactivity with ABO antigens. Finally, to the best of our knowledge, the NLRC5 and DTX3L-PARP9 findings have not been reported in epigenetic studies of other proinflammatory cytokines, although a recent meta-analysis of C-reactive protein reported multiple associations with methylation loci in other interferon pathway genes, 38 demonstrating distinct yet associated epigenetic determinants of the human immune response. Given the inflammatory relevance of the TNF-α phenotype, the use of leukocyte-derived DNA for methylation measurements constitutes a clear strength of the study. Furthermore, the accessibility of blood facilitates future translational applications of the findings (eg, development of risk stratification tools or other personalized approaches). Another strength of our study stems from restricting the main analyses to cohorts that measured TNF-α levels using ELISA tests, considered the gold standard for clinical use, 39 which reduced spurious variation. Third, we achieved independent replication of our top hits in the NFBC66 cohort, increasing confidence in the validity of the findings. Finally, DNA methylation measurements were available in multiple cohorts that also offered genotype and expression data, enabling an integrative approach to identify the mechanisms linking methylation and circulating TNF-α levels.
Limitations
However, several limitations of our integrative analyses must be noted. First, the expression findings replicated robustly between the FHS cohort and RS, but not in the KORA cohort. Possible reasons include discrepancies in population characteristics, gene expression measurements, or chance. Second, the FHS measurements of methylation and TNF-α levels were taken several years apart, while all other cohorts performed them contemporaneously. However, the FHS findings were similar to those derived from cross-sectional studies, and the difference in time between the measurements would bias the effect estimates toward the null, further reassuring our results. Third, the reported associations cannot be interpreted as causal because they were established in observational data that do not preclude bias (eg, because of residual confounding). Causal inference methods such as mendelian randomization, used widely to corroborate findings of epigenome-wide studies, were not optimal for this study because strong genetic instruments for either (1) TNF-α itself or (2) the methylation at the top loci, which we showed to be only weakly related to the genotype were not currently available. Future studies may consider directly assessing the relationship between DNA methylation in NLRC5 and PARP9-DTX3L and systemic inflammation in experimental models.
Conclusions
In summary, we report novel evidence linking DNA methylation in 2 immune response-related regions (NLRC5 and PARP9-DTX3L) with corresponding gene expression, circulating TNF-α levels, and incident CHD in a population-based meta-analysis, highlighting the potential of these regions as translational targets. These findings elucidate the usefulness of hypothesis-free methylome-wide studies in identifying physiologically meaningful phenomena. Together with evidence from in vitro and in vivo functional studies, these findings yield valuable insights into immunopathology of CHD. 
Framingham Heart Study (FHS)
The FHS offspring cohort is a community-based cohort recruited in 1971 and included the offspring (and their spouses) of the FHS original cohort. The eligible sample for this investigation (n=1875) was drawn from participants in the FHS offspring cohort who gave consent for genomic studies and had TNFα assays completed on plasma samples collected at the seventh examination cycle (1998) (1999) (2000) (2001) and DNA methylation assays completed on whole blood samples collected at the eighth examination cycle (2005) (2006) (2007) (2008) . The mean (SD) time between TNFα and DNA methylation measurements was 6.5 (0.7) years. At each examination, participants provided fasting blood samples and had a standardized medical examination, including obtaining smoking history, current medication use, and height and weight. Details are available at http://www.framinghamheartstudy.org/. Participants (n=125) who reported having an auto-immune disease or taking immune modulating agents (oral corticosteroids, hormone replacement therapy, TNFα blockers, etc.) were excluded. After exclusions and assay quality control filtering, the final sample size of 1730 was used in this analysis. The FHS protocols were approved by the Institutional Review Board of Boston University School of Medicine and written informed consents were obtained from all participants. Participant-level phenotype and genotype data from the Framingham Heart Study are accessible from the U.S. National Center for Biotechnology Information (NCBI) database of Genotypes and Phenotypes (dbGaP) at https://dbgap.ncbi.nlm.nih.gov/ to approved scientific investigators pursuing research questions that are consistent with the informed consent agreements provided by individual research participants. The FHS methylation data are available at dbGaP under the accession number phs000724.v2.p9 and gene expression data at accession number phs000363.v3.p6. Participants were not renumerated in any way.
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)
In 2002-2004, GOLDN recruited self-identified European American participants from three-generational families previously participating in the National Heart, Lung, and Blood Institute Family Heart Study at the Minneapolis and Salt Lake City sites. Participants were screened and excluded if they met the following criteria: extreme hypertriglyceridemia (>1500 mg/dL), chronic disease (e.g. cardiovascular, renal, or hepatic conditions), pregnancy/ breastfeeding/ not using contraception. Additionally, participants were excluded if they were acutely sick (e.g. with a cold), had a chronic autoimmune disease, or were using immunomodulating drugs. DNA methylation, TNFα, and all relevant covariates were measured at baseline, during the same examination. The final sample size included 970 individuals who provided informed consent to their use of DNA in research and had the requisite exposure, outcome, and covariate information. All were approved by the Institutional Review Boards of University of Minnesota, University of Utah, University of Alabama at Birmingham, and Tufts University/New England Medical Center; all participants provided written informed consent. Participants were paid $50 per each study visit. Methylation data on GOLDN participants are available at dbGap under the accession number phs000741.v2.p1.
Helsinki Birth Cohort Study (HBCS)
The HBCS comprises 13345 individuals (6370 women and 6975 men), born as singletons between 1934 and 1944 in one of the two main maternity hospitals in Helsinki and who were living in Finland in 1971 when a unique personal identification number was allocated to each member of the Finnish population. The HBCS has been approved by the Ethics Committee of the National Public Health Institute. Register data were linked with permission from the Finnish Ministry of Social Affairs and Health and the Finnish National Archives. In 2001Ð 2004 at an average age of 61.5 years (SD=2.9 and range=56.7Ð69.8 years), a randomly selected subsample of the cohort comprising 2003 individuals (1075 women and 928 men) was invited to a clinical examination including collection of a blood sample for (epi)genetic and biochemical studies, measures of weight and height, and survey on health behaviors, such as smoking, personal characteristics and well-being. Of this sample, assaying TNFα was successful in 1989 participants. For 269 participants, extraction of DNA was not successful, or DNA showed gender discrepancy or close relatedness. The excluded and the included participants did not differ from each other in any of the study variables (P>0.13). From the remaining sample of 1720 individuals, 115 women and 97 men had been evacuated to Sweden and Denmark during World War II according to the Finnish National Archives' register. Methylation profiles were measured in 80 evacuated men and 79 non-evacuated controls matched for sex, birth year and father's occupational status in childhood. In this study, the analyses are based on 78 evacuated men and 76 non-evacuated controls with TNFα levels within 4SD. All participants provided written informed consent, they were not renumerated in any way, and their data are not publicly available. 
Measurements
Framingham Heart Study (FHS) Expression data in FHS were obtained from whole blood samples collected in PaxGeneª tubes (BD Biosciences), collected at the same time as the samples for quantification of DNA methylation, and assayed using the Affymetrix Human Exon Array ST-1.0. The FHS gene expression data are available on dbGAP (accession number: phs000363.v15.p10). The association of DNA methylation with gene expression was examined in 2262 participants. Study-specific covariates were the family structure covariance and technical covariates were row, chip, and column.
Kooperative Gesundheitsforschung in der Region Augsburg (KORA) Whole blood was collected in PAXgeneª tubes (BD Biosciences, Germany) and frozen at −80¡C. RNA was extracted using the whole blood RNA System Kit (Qiagen, Venlo, Netherlands) and mRNA expression profiling was assessed using Illumina HT-12 v3 platform, which contains more than 47,000 probes targeting the expression of ~20,000 genes. Quantile normalization and L2T was performed in R using the lumi package from the Bioconductor open source software (http://www.bioconductor.org/). The methylation-expression associations were examined in 726 participants that had complete measurements that passed quality control. Technical covariates included RNA amplification batch, RNA integrity number (RIN), and sample storage time.
Rotterdam Study (RS) Whole-blood was collected (PAXGeneª tubes, BD Biosciences) and total RNA was isolated (PAXGeneª Blood RNA kits, Qiagen). To ensure a constant high quality of the RNA preparations, all RNA samples were analysed using the Labchip GX (Calliper) according to the manufacturerÕs instructions. Samples with an RNA Quality Score of 7 or higher were amplified and labeled (Ambion TotalPrep RNA), and hybridized to the Illumina HT-12 v4 Expression Beadchips as described by the manufacturerÕs protocol. Processing of the Rotterdam Study RNA samples was performed at the Genetic Laboratory of Internal Medicine, Erasmus University Medical Centre Rotterdam. The RS-III expression dataset is available at GEO (Gene Expression Omnibus) public repository under the accession number GSE33828. Illumina gene expression data was quantile-normalized to the median distribution and subsequently log2-transformed. The probe and sample means were centered to zero. Genes were declared significantly expressed when the detection P values calculated by GenomeStudio were less than 0.05 in more than 10% of all discovery samples, which added to a total number of 21,238 probes. Quality control was done using the eQTL-mapping pipeline. Only probes that uniquely mapped to hg 37 were analyzed. The expression analyses (n=750) considered genomic regions 500kb up-and downstream of the CpG of interest.
Statistical Analysis All three cohorts conducted the expression-methylation association (eQTM) analyses in two stages. First, both DNA methylation β scores and gene expression values were residualized with adjustment for age, sex, imputed cell count proportions, as well as study-specific and technical covariates detailed in eMethods 2. Second, the eQTM linear regression models were fit with the gene expression residual as the dependent variable and the methylation residual as the independent variable. FHS models were additionally adjusted for 25 methylation surrogate variables (SVs) and 25 expression SVs to account for unmeasured technical and batch effects. Statistical significance was established using the Bonferroni threshold of 0.05/number of hypotheses tested, i.e. the number of CpG-gene transcript pairs. Genotyping and Imputation Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) GOLDN participants were genotyped at 906,600 loci using the Human SNP Array 6.0 (Affymetrix). SNPs were excluded from subsequent analyses if they were monomorphic, had a call rate of < 96%, or exhibited Mendel errors as follows: 3+ families with errors if minor allele frequency (MAF) of a given SNP > 20%, 2+ families with errors if 20% ≥ MAF>10%, 1+ family with errors and 10% ≥ MAF>5%, or SNPs with MAF < 5% and Mendel errors in any family. Of 718,452 SNPs that passed quality control procedures described above, only 12 had a Hardy-Weinberg P < 10 -6 . Variants with MAF < 1% were excluded, leaving 654,634 SNPs for imputation. Phase 1 release of 1000 Genomes reference panel was used for imputation, performed with MACH (pre-phasing) and Minimac (imputation) software (Abecasis Lab, Ann Arbor, MI). After merging the typed and imputed data and removing SNPs with imputation r 2 < 0.3 or MAF <1%, 9,432,837 variants were available for the analysis. 690 participants passed quality control and were included in the methylation quantitative trait loci analysis.
The Rotterdam Study (RS) Participants from the RS third cohort (n=3,540) were genotyped using the Human610-Quad BeadChip (Illumina). After excluding samples with the call rate of <97.5% and SNPs with a call rate <95% and Hardy-Weinberg P < 10 -6 , 543,360 SNPs and 3,504 participants remained. To obtain imputed data, more restrictive SNP filters (namely minimum minor allele frequency of 0.01 and SNP call rate of 0.98%) were applied and 514,073 SNPs passed the filters. 2,543,887 SNPs were imputed using phased haplotypes of 1000 Genomes Phase 1 in MACH software. 731 participants with both methylation and genotype data that passed quality control were included in the methylation quantitative trait loci analysis.
Statistical Analysis
In the discovery phase, we created residuals by regressing inverse-normal transformed methylation β scores on the first ten methylation principal components and up to the first ten ancestry principal components. The residuals then served as the dependent variables in a linear regression model with SNPs as predictors. SNPs with low imputation quality (r 2 < 0.4) and low frequency variants (MAF < 0.01) were removed from the analyses. SNPs with the FDR < 0.05 were carried forward to replication. In the replication phase, we fit linear mixed models with the methylation β scores as outcomes, adjusted for age, sex, study site, four CD4+ T-cell purity principal components (fixed effects) and family relatedness (random effect). Due to limited evidence of population stratification in GOLDN, we did not adjust for ancestry. The top CpG sites associated with TNFα are framed in blue; their methylation status (orange= methylated, purple= partially methylated, blue= unmethylated) is displayed by human cell type (top= embryonic stem cells, middle= B-lymphocytes, bottom= umbilical vein endothelial cells). Other overlapping features include, from top to bottom: known genes, messenger RNAs, H3K27Ac histone peaks indicating proximity to regulatory elements, DNase I hypersensitivity clusters, and transcription factors. The top CpG sites associated with TNFα are framed in blue; their methylation status (orange= methylated, purple= partially methylated, blue= unmethylated) is displayed by human cell type (top= embryonic stem cells, middle= B-lymphocytes, bottom= umbilical vein endothelial cells). Other overlapping features include, from top to bottom: known genes, messenger RNAs, H3K27Ac histone peaks indicating proximity to regulatory elements, DNase I hypersensitivity clusters, and transcription factors. 
